Copyright
©The Author(s) 2016.
World J Gastroenterol. Jun 7, 2016; 22(21): 5104-5113
Published online Jun 7, 2016. doi: 10.3748/wjg.v22.i21.5104
Published online Jun 7, 2016. doi: 10.3748/wjg.v22.i21.5104
Figure 2 Change in body weight from baseline on each baseline factor during the first week of tolvaptan administration.
Data are expressed as median. Patients were divided into two groups using the median value of each baseline variable: (A) serum BUN; (B) serum creatinine; (C) serum eGFR; (D) urine osmolality; (E) Child-Pugh Score (CPS); (F) serum albumin (Alb); (G) serum hyaluronic acid; and (H) Hepatic venous pressure gradient (HVPG).
- Citation: Nakagawa A, Atsukawa M, Tsubota A, Kondo C, Okubo T, Arai T, Itokawa N, Narahara Y, Iwakiri K. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World J Gastroenterol 2016; 22(21): 5104-5113
- URL: https://www.wjgnet.com/1007-9327/full/v22/i21/5104.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i21.5104